Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Auckland. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
New Zealand Clinical Research is trialling an investigational medication that is being developed for the treatment of conditions affected by muscle loss due to ageing.
Azelaprag works by binding to and activating the apelin reception (APJ). Levels of Apelin decreases as you age. Azelaprag acts to mimic Apelin to increase muscle renewal and growth and may treat conditions that result in muscle loss. The APJ receptor may influence a range of body processes such as heart function, immune signalling, and blood sugar processing. It is hoped that, by activating the APJ receptor, azelaprag may improve conditions affecting muscle loss due to ageing.
It is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
Study Candidtes
- Healthy Males and Females of non-childbearing potential
- Aged 60 years or over
- BMI 18 – 40 kg/m2
- Non-smokers
- Any medication will be recorded and reviewed
What is Involved?
Overnight stay: 15-night stay
Follow-up visits: 4 follow-up visits
Reimbursement: $9,000 (less tax)